CNTX vs. PRQR, INZY, TRDA, ACB, IMMP, NBTX, FENC, TKNO, EDIT, and SCPH
Should you be buying Context Therapeutics stock or one of its competitors? The main competitors of Context Therapeutics include ProQR Therapeutics (PRQR), Inozyme Pharma (INZY), Entrada Therapeutics (TRDA), Aurora Cannabis (ACB), Prima BioMed (IMMP), Nanobiotix (NBTX), Adherex Technologies (FENC), Alpha Teknova (TKNO), Editas Medicine (EDIT), and scPharmaceuticals (SCPH). These companies are all part of the "pharmaceutical products" industry.
Context Therapeutics vs. Its Competitors
Context Therapeutics (NASDAQ:CNTX) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.
In the previous week, Context Therapeutics had 1 more articles in the media than ProQR Therapeutics. MarketBeat recorded 2 mentions for Context Therapeutics and 1 mentions for ProQR Therapeutics. Context Therapeutics' average media sentiment score of 1.66 beat ProQR Therapeutics' score of 0.00 indicating that Context Therapeutics is being referred to more favorably in the media.
Context Therapeutics currently has a consensus target price of $5.50, indicating a potential upside of 554.14%. ProQR Therapeutics has a consensus target price of $8.00, indicating a potential upside of 253.98%. Given Context Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Context Therapeutics is more favorable than ProQR Therapeutics.
Context Therapeutics has higher earnings, but lower revenue than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.
14.0% of Context Therapeutics shares are owned by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are owned by institutional investors. 2.8% of Context Therapeutics shares are owned by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Context Therapeutics has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -157.04%. Context Therapeutics' return on equity of -29.78% beat ProQR Therapeutics' return on equity.
Context Therapeutics has a beta of 1.88, indicating that its stock price is 88% more volatile than the S&P 500. Comparatively, ProQR Therapeutics has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500.
Summary
Context Therapeutics beats ProQR Therapeutics on 10 of the 15 factors compared between the two stocks.
Get Context Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Context Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CNTX) was last updated on 7/24/2025 by MarketBeat.com Staff
